MyFinsight
Home
Blog
About
Contact
Download
Download image
something is missing
$67,069K
Loss from change in
fair value of...
-$49,229K
Share-based compensation
$10,596K
Depreciation of fixed assets
and amortization of...
$8,216K
Accounts receivable
-$6,409K
Non-cash income from
financial royalty assets
-$4,796K
Accounts payable and
accrued liabilities
$2,714K
Loss on derivative
instruments
-$837K
Amortization of debt discount
and issuance fees
$803K
Income tax receivable
and payable
-$695K
Change in estimated
fair value of...
-$624K
Lease amortization
expense
$479K
Other assets and
liabilities
-$207K
Cecl adjustment to
financial royalty assets
$21K
Net decrease in
cash, cash...
-$59,833K
Canceled cashflow
$67,069K
Net cash provided by
(used in) operating...
$48,691K
Canceled cashflow
$36,935K
Net decrease in
cash, cash...
-$126,902K
Canceled cashflow
$48,691K
Proceeds from maturity of
short-term investments
$119,350K
Proceeds from financial
royalty assets
$6,979K
Proceeds from sale of
short-term investments
$1,300K
Proceeds from sale of
derivatives
$431K
Net proceeds from
stock option...
$7,654K
Deferred income taxes,
net
$13,532K
Net loss
-$13,345K
Inventory
$4,140K
(gain) loss from
short-term investments
$3,869K
Accretion of short-term
investments
$1,502K
Other
-$547K
Net cash (used in)
provided by investing...
-$94,347K
something is missing
-$67,069K
Canceled cashflow
$128,060K
Net cash used in
financing activities
-$14,133K
Effect of exchange rate
changes on cash and cash...
-$44K
Canceled cashflow
$7,654K
Purchases of short-term
investments
$222,179K
Purchases of property and
equipment
$228K
Taxes paid related to
net share...
$21,730K
Debt discount and
payment of debt issuance...
$50K
Payments under finance
lease obligations
$7K
Back
Back
Cash Flow
LIGAND PHARMACEUTICALS INC (LGNZZ)
LIGAND PHARMACEUTICALS INC (LGNZZ)
source: myfinsight.com